Fibroblasts as a Biological Marker for Curative Resection in Pancreatic Ductal Adenocarcinoma

Int J Mol Sci. 2020 May 29;21(11):3890. doi: 10.3390/ijms21113890.

Abstract

Achievement of microscopic tumor clearance (R0) after pancreatic ductal adenocarcinoma (PDAC) surgery is determined by cancer biology rather than operative technique. Fibroblasts are known to play pro-cancer roles; however, a small subset was recently found to play anti-cancer roles. Therefore, we hypothesized that intratumor fibroblasts contribute to curative resection and a better survival of PDAC. Utilizing a large, publicly available PDAC cohort, we found that fibroblast composition was associated with R0 curative resection. A high amount of fibroblasts in PDACs was significantly associated with a higher amount of mature vessels, but not with blood angiogenesis. A high amount of fibroblasts was also associated with a higher infiltration of anti-cancer immune cells, such as CD8+ T-cells and dendritic cells, together with higher inflammatory signaling, including IL2/STAT5 and IL6/JAK/STAT3 signaling. Further, the fibroblast composition was inversely associated with cancer cell composition in the bulk tumor, along with an inverse association with proliferative characteristics, such as MYC signaling and glycolysis. The patients with high-fibroblast PDACs showed an improved prognosis. In conclusion, we found that PDACs with high fibroblasts were associated with a higher R0 resection rate, resulting in a better prognosis. These findings may be due to less aggressive biology with a higher vascularity and anti-cancer immunity, and a low cancer cell component.

Keywords: fibroblast; pancreatic cancer; residual tumor; vascularity.

MeSH terms

  • Adenocarcinoma / pathology*
  • Adenocarcinoma / surgery*
  • Aged
  • Algorithms
  • Antineoplastic Agents / pharmacology
  • Biomarkers, Tumor
  • CD8-Positive T-Lymphocytes / cytology
  • Carcinoma, Pancreatic Ductal / pathology*
  • Carcinoma, Pancreatic Ductal / surgery*
  • Databases, Factual
  • Female
  • Fibroblasts / cytology*
  • Fibrosis
  • Glycolysis
  • Humans
  • Male
  • Middle Aged
  • Neovascularization, Pathologic
  • Prognosis
  • Time Factors
  • Transcriptome
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor